Simulating outcomes of untreated patients – can we reduce the placebo group?

Manfred Berres, René Spiegel, Andreas U. Monsch & André R. Miserez
Introduction: We consider the scenario of a new drug with a potential to stop the progression of a disease with no effective competitor being available. The routinely used design for phase III clinical studies is a randomized placebo-controlled trial. This means that many patients receive placebo for[for full text, please go to the a.m. URL]